Moderna, Inc. today announced that it has been awarded a contract for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia.
The participating countries will be able to order up to 146 million doses of the mRNA COVID-19 vaccine, as needed depending on national context and with no minimum amount of doses to be bought. The contract will run for a period of up to four years.
Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease the risk of administration errors and save time, which may ultimately improve vaccination campaign efficiency.
“I welcome today’s announcement which shows our sustained efforts to enhance preparedness and secure supply of medical countermeasures to protect the most vulnerable against COVID-19,” stated Hadja Lahbib, Commissioner for Equality, Preparedness and Crisis Management. “This particular vaccine, with an accessible supply of up to 146 million doses, offers significant advantages: it can be stored in standard freezers used for routine vaccines and can be delivered in pre-filled syringes.”
These features improve the efficiency of vaccination campaigns, which is particularly important when reaching those most in need. Strengthened health security remains an essential component of our Preparedness Union.”
In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna’s COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.
The procurement framework with Moderna was spearheaded by the European Commission’s Health Emergency Preparedness and Response Authority (HERA).
Sources: European Commission, Moderna